Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of four new drugs, indicating a significant advancement in its oncology pipeline [1] Group 1: Drug Approvals - Heng Rui Medicine and its subsidiaries have been granted clinical trial approval for HRS-4508 tablets, SHR-A1811 injection, Adebeli monoclonal antibody injection, and Bevacizumab injection [1] - HRS-4508 is a novel, highly selective tyrosine kinase inhibitor that inhibits tumor cell proliferation to exert anti-tumor effects [1] - SHR-A1811 injection binds to HER2-expressing tumor cells, inducing apoptosis through a unique mechanism involving lysosomal release of toxins [1] Group 2: Immunotherapy Developments - Adebeli monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody developed by Heng Rui Medicine, which reactivates the immune system's anti-tumor activity by blocking the PD-1/PD-L1 pathway [1] - Bevacizumab is a humanized anti-VEGF monoclonal antibody, further expanding the company's oncology treatment options [1]